METTL3-Mediated N6-Methyladenosine Modification Is Involved in the Dysregulation of NRIP1 Expression in Down Syndrome

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 Apr 19

PMID 33869171

Citations 6

Authors

Weili Shi

Fan Yang

Ranran Dai

Yafei Sun

Yan Chu

Shixiu Liao

Bingtao Hao

Affiliations

Soon will be listed here.

Abstract

Down syndrome (DS) is a common genetic condition in which a person is born with an extra copy of chromosome 21. Intellectual disability is the most common characteristic of DS. N6-methyladenosine (m6A) is a common RNA modification that is implicated in many biological processes. It is highly enriched within the brain and plays an essential role in human brain development. However, the mRNA m6A modification in the fetal brain of DS has not been explored. Here, we report m6A mRNA profiles and mRNA expression profiles of fetal brain cortex tissue from DSs and controls. We observed that the m6A modification in DS brain tissues was reduced genome-wide, which may be due to decreased the m6A methyltransferase like 3 (METTL3) protein expression. The nuclear receptor-interacting protein 1 () is coded by a highly conserved chromosome 21 (Hsa21) gene. Overexpression of NRIP1 is associated with mitochondrial dysfunction in DS. The NRIP1 mRNA increased in fetal brain tissues of DS, whereas the m6A modification of the NRIP1 mRNA significantly decreased. METTL3 knockdown reduced the m6A modification of NRIP1 mRNA and increased its expression, and an increase in NRIP1 m6A modification and a decrease in its expression were observed in METTL3-overexpressed cells. The Luciferase reporter assay confirmed that METTL3 regulates NRIP1 expression in an m6A-dependent manner. The decay rate of NRIP1 mRNA was significantly reduced in METTL3-knockdown cells but increased in METTL3-overexpressed cells. We proposed that the m6A modification of NRIP1 mRNA in DS fetal brain tissue is reduced, reducing its transcript degradation rate, resulting in abnormally increased expression of NRIP1, at least partially, in the DS brain. It provides a new mechanism for the molecular pathology of DS and leads to a new insight that may become therapeutically relevant.

Citing Articles

Methyltransferase METTL3 governs the modulation of SH3BGR expression through m6A methylation modification, imparting influence on apoptosis in the context of Down syndrome-associated cardiac development.

Shi W, Chen R, Zhou M, Li Y, Zhang Y, Wang J Cell Death Discov. 2024; 10(1):396.

PMID: 39237501 PMC: 11377721. DOI: 10.1038/s41420-024-02164-3.

Integration of ATAC-seq and RNA-seq identifies MX1-mediated AP-1 transcriptional regulation as a therapeutic target for Down syndrome.

Guo Z, Zhu Y, Xiao H, Dai R, Yang W, Xue W Biol Res. 2023; 56(1):67.

PMID: 38066591 PMC: 10709892. DOI: 10.1186/s40659-023-00474-x.

m6A genotypes and prognostic signature for assessing the prognosis of patients with acute myeloid leukemia.

Fu C, Kou R, Meng J, Jiang D, Zhong R, Dong M BMC Med Genomics. 2023; 16(1):191.

PMID: 37596597 PMC: 10436408. DOI: 10.1186/s12920-023-01629-1.

The role and regulatory mechanism of mA methylation in the nervous system.

Jiang L, Li X, Wang S, Yuan Z, Cheng J Front Genet. 2022; 13:962774.

PMID: 36118889 PMC: 9474891. DOI: 10.3389/fgene.2022.962774.

RNA N6-Methyladenosine Modifications and Its Roles in Alzheimer's Disease.

Zhang R, Zhang Y, Guo F, Li S, Cui H Front Cell Neurosci. 2022; 16:820378.

PMID: 35401117 PMC: 8989074. DOI: 10.3389/fncel.2022.820378.

References

Lee Y, Choe J, Park O, Kim Y . Molecular Mechanisms Driving mRNA Degradation by mA Modification. Trends Genet. 2020; 36(3):177-188. DOI: 10.1016/j.tig.2019.12.007. View

Piccoli C, Izzo A, Scrima R, Bonfiglio F, Manco R, Negri R . Chronic pro-oxidative state and mitochondrial dysfunctions are more pronounced in fibroblasts from Down syndrome foeti with congenital heart defects. Hum Mol Genet. 2012; 22(6):1218-32. DOI: 10.1093/hmg/dds529. View

Du T, Rao S, Wu L, Ye N, Liu Z, Hu H . An association study of the m6A genes with major depressive disorder in Chinese Han population. J Affect Disord. 2015; 183:279-86. DOI: 10.1016/j.jad.2015.05.025. View

Dominissini D, Moshitch-Moshkovitz S, Salmon-Divon M, Amariglio N, Rechavi G . Transcriptome-wide mapping of N(6)-methyladenosine by m(6)A-seq based on immunocapturing and massively parallel sequencing. Nat Protoc. 2013; 8(1):176-89. DOI: 10.1038/nprot.2012.148. View

Blondrath K, Steel J, Katsouri L, Ries M, Parker M, Christian M . The nuclear cofactor receptor interacting protein-140 (RIP140) regulates the expression of genes involved in Aβ generation. Neurobiol Aging. 2016; 47:180-191. DOI: 10.1016/j.neurobiolaging.2016.08.003. View

Shi W, Xu G, Wang C, Sperber S, Chen Y, Zhou Q . Heat shock 70-kDa protein 5 (Hspa5) is essential for pronephros formation by mediating retinoic acid signaling. J Biol Chem. 2014; 290(1):577-89. PMC: 4281759. DOI: 10.1074/jbc.M114.591628. View

Wolvetang E, Bradfield O, Tymms M, Zavarsek S, Hatzistavrou T, Kola I . The chromosome 21 transcription factor ETS2 transactivates the beta-APP promoter: implications for Down syndrome. Biochim Biophys Acta. 2003; 1628(2):105-10. DOI: 10.1016/s0167-4781(03)00121-0. View

Zheng G, Dahl J, Niu Y, Fedorcsak P, Huang C, Li C . ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2012; 49(1):18-29. PMC: 3646334. DOI: 10.1016/j.molcel.2012.10.015. View

Shi W, Liu Z, Wang H, Wu D, Zhang H, Xiao H . Integrated miRNA and mRNA expression profiling in fetal hippocampus with Down syndrome. J Biomed Sci. 2016; 23(1):48. PMC: 4897952. DOI: 10.1186/s12929-016-0265-0. View

10.

Gardiner K, Costa A . The proteins of human chromosome 21. Am J Med Genet C Semin Med Genet. 2006; 142C(3):196-205. PMC: 3299406. DOI: 10.1002/ajmg.c.30098. View

11.

Wang X, Lu Z, Gomez A, Hon G, Yue Y, Han D . N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2013; 505(7481):117-20. PMC: 3877715. DOI: 10.1038/nature12730. View

12.

Chen J, Zhang Y, Huang C, Shen H, Sun B, Cheng X . mA Regulates Neurogenesis and Neuronal Development by Modulating Histone Methyltransferase Ezh2. Genomics Proteomics Bioinformatics. 2019; 17(2):154-168. PMC: 6620265. DOI: 10.1016/j.gpb.2018.12.007. View

13.

Arai Y, Iwasaki Y, Suzuki T, Ide S, Kaga M . Elimination of amyloid precursor protein in senile plaques in the brain of a patient with Alzheimer-type dementia and Down syndrome. Brain Dev. 2018; 41(1):106-110. DOI: 10.1016/j.braindev.2018.07.017. View

14.

Fu Y, Dominissini D, Rechavi G, He C . Gene expression regulation mediated through reversible m⁶A RNA methylation. Nat Rev Genet. 2014; 15(5):293-306. DOI: 10.1038/nrg3724. View

15.

Lapierre M, Docquier A, Castet-Nicolas A, Gitenay D, Jalaguier S, Teyssier C . The emerging role of the transcriptional coregulator RIP140 in solid tumors. Biochim Biophys Acta. 2015; 1856(1):144-50. DOI: 10.1016/j.bbcan.2015.06.006. View

16.

Conti A, Fabbrini F, DAgostino P, Negri R, Greco D, Genesio R . Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. BMC Genomics. 2007; 8:268. PMC: 1964766. DOI: 10.1186/1471-2164-8-268. View

17.

Dierssen M . Down syndrome: the brain in trisomic mode. Nat Rev Neurosci. 2012; 13(12):844-58. DOI: 10.1038/nrn3314. View

18.

Izzo A, Mollo N, Nitti M, Paladino S, Cali G, Genesio R . Mitochondrial dysfunction in down syndrome: molecular mechanisms and therapeutic targets. Mol Med. 2018; 24(1):2. PMC: 6016872. DOI: 10.1186/s10020-018-0004-y. View

19.

Izzo A, Manco R, Bonfiglio F, Cali G, de Cristofaro T, Patergnani S . NRIP1/RIP140 siRNA-mediated attenuation counteracts mitochondrial dysfunction in Down syndrome. Hum Mol Genet. 2014; 23(16):4406-19. DOI: 10.1093/hmg/ddu157. View

20.

Wisniewski K, Dalton A, McLachlan C, Wen G, Wisniewski H . Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology. 1985; 35(7):957-61. DOI: 10.1212/wnl.35.7.957. View